New Brunswick Drugs for Rare Diseases Plan
Health
Overview
The New Brunswick Drugs for Rare Diseases Plan provides assistance with the cost of certain drugs for specific rare diseases.
Eligibility
Individuals must be a permanent resident of New Brunswick and have a valid Medicare card.
A request form for a listed drug must be completed by the physician and the individual must meet the clinical criteria for the drug requested. Request forms may be obtained by calling 1-800-332-3692.
Description
The Plan will consider requests for coverage of the following drugs for specific rare diseases. Requests for coverage for New Brunswick patients are assessed by Ontario Public Drug Programs’ external medical experts using the same clinical criteria.
1. Aldurazyme (laronidase) for the treatment of Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I)
2. Elaprase (idursulfase) for the treatment of Hunter's Syndrome
3. Ilaris (canakinumab) for the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS) - Muckle-Wells Syndrome (MWS) and Neonatal-Onset Multisystem Inflammatory Disease (NOMID) only.
4. Myozyme (alglucosidase alfa) for infantile/early and adult/late onset Pompe disease
5. Naglazyme (galsulfase) for the treatment of Mucopolysaccharidosis VI (MPS VI)
6. Zavesca (miglustat) for the treatment of Niemann Pick Type C (NPC)
The drugs included in the New Brunswick Drugs for Rare Diseases (DRD) Plan were evaluated through the Ontario Drugs for Rare Diseases Framework which is no longer in place. Therefore, no additional drugs will be added to the NB DRD Plan.
All new DRDs are evaluated on behalf of the participating federal, provincial and territorial public drug plans by the Canadian Agency for Drugs and Technologies in Health (CADTH), using the same Health Technology Assessment process as for other drugs. An expert committee reviews the clinical and economic evidence and issues a recommendation to the drug plans on whether a drug should be reimbursed. Each jurisdiction makes their formulary reimbursement decision based on the committee’s recommendation and other factors such as drug plan mandates, jurisdictional priorities, budget impact and resources.
Find contact information here